Atossa Genetics receives positive interim review from independent safety committee
Atossa Genetics announced it has received a positive interim review on its Phase 1 study of topical endoxifen in men, which is being developed to address gynecomastia, which is a common condition in patients being treated for prostate cancer. April 24, 2018